- Home
- HBI vs PTGX Comparison
HBI vs PTGX Comparison
Compare HBI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBI
- PTGX
- Stock Information
- Founded
- HBI 1901
- PTGX 2006
- Country
- HBI United States
- PTGX United States
- Employees
- HBI N/A
- PTGX N/A
- Industry
- HBI Clothing/Shoe/Accessory Stores
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- HBI Consumer Discretionary
- PTGX Health Care
- Exchange
- HBI Nasdaq
- PTGX Nasdaq
- Market Cap
- HBI 2.5B
- PTGX 2.8B
- IPO Year
- HBI 2006
- PTGX 2016
- Fundamental
- Price
- HBI $8.19
- PTGX $41.65
- Analyst Decision
- HBI Hold
- PTGX Strong Buy
- Analyst Count
- HBI 5
- PTGX 7
- Target Price
- HBI $6.00
- PTGX $53.57
- AVG Volume (30 Days)
- HBI 6.5M
- PTGX 700.6K
- Earning Date
- HBI 11-07-2024
- PTGX 11-07-2024
- Dividend Yield
- HBI N/A
- PTGX N/A
- EPS Growth
- HBI N/A
- PTGX N/A
- EPS
- HBI N/A
- PTGX 2.68
- Revenue
- HBI $5,466,904,000.00
- PTGX $323,795,000.00
- Revenue This Year
- HBI N/A
- PTGX $396.93
- Revenue Next Year
- HBI $0.22
- PTGX N/A
- P/E Ratio
- HBI N/A
- PTGX $15.15
- Revenue Growth
- HBI 25.57
- PTGX 125.73
- 52 Week Low
- HBI $3.58
- PTGX $16.80
- 52 Week High
- HBI $8.70
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- HBI 61.17
- PTGX 41.01
- Support Level
- HBI $6.98
- PTGX $33.31
- Resistance Level
- HBI $8.60
- PTGX $48.86
- Average True Range (ATR)
- HBI 0.41
- PTGX 2.82
- MACD
- HBI 0.05
- PTGX -0.62
- Stochastic Oscillator
- HBI 70.06
- PTGX 53.63
About HBI Hanesbrands Inc.
Hanesbrands manufactures basic and athletic apparel under brands including Hanes, Playtex, Maidenform, Bali, Berlei, and Bonds. The company sells wholesale to discount, midmarket, and department store retailers as well as direct to consumers through stores and e-commerce. Hanesbrands is vertically integrated as it produces more than 70% of its products in company-controlled factories in more than three dozen nations. Hanesbrands distributes products in the Americas and Asia-Pacific. The company was founded in 1901 and is based in Winston-Salem, North Carolina.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.